678 related articles for article (PubMed ID: 20457512)
1. Effects of olanzapine and risperidone on lipid metabolism in chronic schizophrenic patients with long-term antipsychotic treatment: a randomized five month study.
Smith RC; Lindenmayer JP; Hu Q; Kelly E; Viviano TF; Cornwell J; Vaidhyanathaswamy S; Marcovina S; Davis JM
Schizophr Res; 2010 Jul; 120(1-3):204-9. PubMed ID: 20457512
[TBL] [Abstract][Full Text] [Related]
2. Effects of olanzapine and risperidone on glucose metabolism and insulin sensitivity in chronic schizophrenic patients with long-term antipsychotic treatment: a randomized 5-month study.
Smith RC; Lindenmayer JP; Davis JM; Kelly E; Viviano TF; Cornwell J; Hu Q; Khan A; Vaidhyanathaswamy S
J Clin Psychiatry; 2009 Nov; 70(11):1501-13. PubMed ID: 19814947
[TBL] [Abstract][Full Text] [Related]
3. Olanzapine and risperidone effects on appetite and ghrelin in chronic schizophrenic patients.
Smith RC; Rachakonda S; Dwivedi S; Davis JM
Psychiatry Res; 2012 Oct; 199(3):159-63. PubMed ID: 22475524
[TBL] [Abstract][Full Text] [Related]
4. A retrospective comparison of weight, lipid, and glucose changes between risperidone- and olanzapine-treated inpatients: metabolic outcomes after 1 year.
Meyer JM
J Clin Psychiatry; 2002 May; 63(5):425-33. PubMed ID: 12019668
[TBL] [Abstract][Full Text] [Related]
5. Differential effects of olanzapine and risperidone on plasma adiponectin levels over time: results from a 3-month prospective open-label study.
Wampers M; Hanssens L; van Winkel R; Heald A; Collette J; Peuskens J; Reginster JY; Scheen A; De Hert M
Eur Neuropsychopharmacol; 2012 Jan; 22(1):17-26. PubMed ID: 21511441
[TBL] [Abstract][Full Text] [Related]
6. Clozapine, risperidone, olanzapine, and conventional antipsychotic drug effects on glucose, lipids, and leptin in schizophrenic patients.
Smith RC; Lindenmayer JP; Bark N; Warner-Cohen J; Vaidhyanathaswamy S; Khandat A
Int J Neuropsychopharmacol; 2005 Jun; 8(2):183-94. PubMed ID: 15737248
[TBL] [Abstract][Full Text] [Related]
7. [Metabolic side effects of risperidone in early onset schizophrenia].
Goeb JL; Marco S; Duhamel A; Kechid G; Bordet R; Thomas P; Delion P; Jardri R
Encephale; 2010 Jun; 36(3):242-52. PubMed ID: 20620267
[TBL] [Abstract][Full Text] [Related]
8. Cross-sectional comparison of fasting lipids in normoglycemic patients with schizophrenia during chronic treatment with olanzapine, risperidone, or typical antipsychotics.
Hardy TA; Marquez E; Kryzhanovskaya L; Taylor CC; Cavazzoni P
J Clin Psychopharmacol; 2006 Aug; 26(4):405-8. PubMed ID: 16855460
[TBL] [Abstract][Full Text] [Related]
9. Metabolic risk with second-generation antipsychotic treatment: a double-blind randomized 8-week trial of risperidone and olanzapine.
Kelly DL; Conley RR; Love RC; Morrison JA; McMahon RP
Ann Clin Psychiatry; 2008; 20(2):71-8. PubMed ID: 18568578
[TBL] [Abstract][Full Text] [Related]
10. [The stabilizing effect of dehydroepiandrosterone on clinical parameters of metabolic syndrome in patients with schizophrenia treated with olanzapine - a randomized, double-blind trial].
Holka-Pokorska JA; Radzio R; Jarema M; Wichniak A
Psychiatr Pol; 2015; 49(2):363-76. PubMed ID: 26093599
[TBL] [Abstract][Full Text] [Related]
11. Sex difference in effects of typical and atypical antipsychotics on glucose-insulin homeostasis and lipid metabolism in first-episode schizophrenia.
Wu RR; Zhao JP; Zhai JG; Guo XF; Guo WB
J Clin Psychopharmacol; 2007 Aug; 27(4):374-9. PubMed ID: 17632222
[TBL] [Abstract][Full Text] [Related]
12. Effects of typical and atypical antipsychotics on glucose-insulin homeostasis and lipid metabolism in first-episode schizophrenia.
Wu RR; Zhao JP; Liu ZN; Zhai JG; Guo XF; Guo WB; Tang JS
Psychopharmacology (Berl); 2006 Jul; 186(4):572-8. PubMed ID: 16601995
[TBL] [Abstract][Full Text] [Related]
13. Double-blind comparison of first- and second-generation antipsychotics in early-onset schizophrenia and schizo-affective disorder: findings from the treatment of early-onset schizophrenia spectrum disorders (TEOSS) study.
Sikich L; Frazier JA; McClellan J; Findling RL; Vitiello B; Ritz L; Ambler D; Puglia M; Maloney AE; Michael E; De Jong S; Slifka K; Noyes N; Hlastala S; Pierson L; McNamara NK; Delporto-Bedoya D; Anderson R; Hamer RM; Lieberman JA
Am J Psychiatry; 2008 Nov; 165(11):1420-31. PubMed ID: 18794207
[TBL] [Abstract][Full Text] [Related]
14. Allelic variation in ApoC3, ApoA5 and LPL genes and first and second generation antipsychotic effects on serum lipids in patients with schizophrenia.
Smith RC; Segman RH; Golcer-Dubner T; Pavlov V; Lerer B
Pharmacogenomics J; 2008 Jun; 8(3):228-36. PubMed ID: 17726453
[TBL] [Abstract][Full Text] [Related]
15. Prediction of long-term metabolic effects of olanzapine and risperidone treatment from baseline body mass index in schizophrenia and bipolar disorder.
Bobo WV; Bonaccorso S; Jayathilake K; Meltzer HY
Psychiatry Res; 2011 Sep; 189(2):200-7. PubMed ID: 21802150
[TBL] [Abstract][Full Text] [Related]
16. A 12-week randomized clinical trial to evaluate metabolic changes in drug-naive, first-episode psychosis patients treated with haloperidol, olanzapine, or risperidone.
Perez-Iglesias R; Crespo-Facorro B; Amado JA; Garcia-Unzueta MT; Ramirez-Bonilla ML; Gonzalez-Blanch C; Martinez-Garcia O; Vazquez-Barquero JL
J Clin Psychiatry; 2007 Nov; 68(11):1733-40. PubMed ID: 18052567
[TBL] [Abstract][Full Text] [Related]
17. Comparison of fasting blood sugar and serum lipid profile changes after treatment with atypical antipsychotics olanzapine and risperidone.
Kaushal J; Bhutani G; Gupta R
Singapore Med J; 2012 Jul; 53(7):488-92. PubMed ID: 22815019
[TBL] [Abstract][Full Text] [Related]
18. Longitudinal effect of olanzapine on fasting serum lipids: a randomized, prospective, 4-month study.
Kinon BJ; Liu-Seifert H; Ahl J; Ahmed S; Baker RW
Ann N Y Acad Sci; 2004 Dec; 1032():295-6. PubMed ID: 15677433
[TBL] [Abstract][Full Text] [Related]
19. Effects of switching from olanzapine to risperidone on the prevalence of the metabolic syndrome in overweight or obese patients with schizophrenia or schizoaffective disorder: analysis of a multicenter, rater-blinded, open-label study.
Meyer JM; Pandina G; Bossie CA; Turkoz I; Greenspan A
Clin Ther; 2005 Dec; 27(12):1930-41. PubMed ID: 16507379
[TBL] [Abstract][Full Text] [Related]
20. A comparison of weight change during treatment with olanzapine or aripiprazole: results from a randomized, double-blind study.
McQuade RD; Stock E; Marcus R; Jody D; Gharbia NA; Vanveggel S; Archibald D; Carson WH
J Clin Psychiatry; 2004; 65 Suppl 18():47-56. PubMed ID: 15600384
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
